C4 Therapeutics, Inc. (CCCC)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew J. Hirsch M.B.A. | CEO, President & Director | 971k | -- | 1971 |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director & Member of Scientific Advisory Board | 39.03k | -- | 1951 |
| Dr. Stewart Fisher | Chief Scientific Officer | 657.34k | -- | 1967 |
| Mr. Scott N. Boyle M.B.A., Ph.D. | Chief Business Officer | 672.78k | -- | 1978 |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Ms. Kendra Adams | Chief Financial Officer | -- | -- | -- |
| Mr. Mark Mossler | Chief Accounting Officer | -- | -- | 1973 |
| Ms. Jolie M. Siegel J.D. | Chief Legal Officer & Corporate Secretary | 610.4k | 1.06M | 1977 |
| Ms. Kelly A. Schick | Chief People Officer | -- | -- | 1980 |
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances & Business Development | -- | -- | -- |
C4 Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 145
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Recent Events
- Apr 10, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing
- Mar 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 04, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 22, 2024S-8: Offering RegistrationsSee Full Filing
- Feb 14, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing